key: cord-0897437-bt6ew2io authors: Casella, Donato; Fusario, Daniele; Cassetti, Dario; Miccoli, Simone; Pesce, Anna Lisa; Bernini, Andrea; Marcasciano, Marco; Lo Torto, Federico; Neri, Alessandro title: The patient’s pathway for breast cancer in the COVID‐19 era: An Italian single‐center experience date: 2020-06-28 journal: Breast J DOI: 10.1111/tbj.13958 sha: 70db8bc3d20a5b6711ea2295bc0caea6c351f749 doc_id: 897437 cord_uid: bt6ew2io COVID‐19 has been declared a pandemic by the World Health Organization. As of April 1, 2020, Italy was the country with the second highest number of cases in the world. The spread of COVID‐19 has required a rapid reorganization of health service delivery in face of the pandemic. Breast cancer units have reprioritized their workload to guarantee the health of oncologic patients at the highest risk and regular screening activities. However, at the end of the pandemic emergency, many benign and reconstructive cases will return to our attention and their surgical treatment will be necessary as soon as possible. COVID-19 has been declared a pandemic by the World Health Organization (WHO) with 827 419 cases across 206 countries worldwide and 40.777 deaths as of April 1, 2020. 1 After the first outbreak in the Chinese province of Wuhan, Italy was the second most affected country with 102 669 cases (10.007 among health workers) and 11 875 deaths. 2 The virus spread was very rapid and, the Italian government ordered the national lockdown on March 10, 2020. As a consequence, a substantial reorganization of the Italian National and Regional Healthcare Services was implemented in order to reallocate resources and operators to face the virus emergency, while continuing to guarantee treatments of emergencies and chronic and oncologic patients. Indeed, breast cancer units are working to take care of the health of oncologic breast patients and to assure the regular provision of screening activities. The aim of this short communication was to report our experience with the management of breast cancer in the COVID-19 era in order to share our experience and provide information useful to develop possible organization model in countries that are facing this health emergency. Breast cancer screening and diagnosis are done by breast radiologists in compliance with the European Society of Breast Cancer Specialists (EUSOMA) guidelines. 3 While screenings have been suspended, the activities of diagnosis for women with breast symptoms have been maintained active during the COVID-19 emergency, with a reorganization of spaces and schedules in order to minimize the flow of patients to the breast radiology services. Despite such precautional approach aimed at preserving care of patients at the highest care need, we are witnessing a marked decrease in the number of first diagnosis of breast cancers and an increase in patients' withdrawals due to fear of hospital contagion. In all cases of newly diagnosed breast cancer, a member of the MDT, usually the radiologist who did the diagnosis, conducted a first clinical examination of patients. As indicated by the EUSOMA 3 guidelines, the MDT meets once a week: This activity replaces faceto-face meetings with telematic conferences in order to preserve the health of the MDT components. The regular implementation of this new way of working appears to have no negative impact on the quality of work, guaranteeing greater serenity for the MDT meeting components. The need to separate the COVID-19 patients from the other patients has changed the hospital structural organization. Our hospital has been divided into two major blocks. The COVID-19 block includes an intensive care unit, a new para-intensive department, an imaging service, a surgical theater, and a section for the mild cases. The ordinary block is for oncologic COVID-19-negative patients and includes the surgical oncology units. Patients scheduled for breast surgery are screened with a pre-admission oropharyngeal swab to test for COVID-19 with polymerase chain reaction tests. This test is made the day before surgery, and a dedicated new structure outside the main building has been created, where patients wait for the result in separate rooms. Only patients who tested negative for COVID-19 are admitted to the ordinary block for surgical treatment. In the first phase, no specific guidelines for surgery-related risk situations, such as patient's expectorate production during intuba- The surgical team composition has also changed. Our unit includes three senior surgeons and three residents and is now divided into three single teams, which never come into physical contact in order to reduce the risk of contagion. The surgical postoperative follow-up is affected by the restrictions applying to all hospital activities. The outpatient clinic of the breast surgical unit has been reduced from 6 to 3 days per week. The appointment time table has been organized balancing the timing of surgical consult and medication to avoid patient overlapping, and spaces have been made available to guarantee the distances between persons as indicated by the WHO 6 and ISS. 2 Furthermore, the hospital has organized checkpoints at any hospital entrance for measuring the body temperature off staff and hospital users, and has extensively distributed alcohol-based gel for hand cleaning. The spread of the COVID-19 infection has changed our habits and made necessary a rapid reorganization of health services to deal with the pandemic. Although the efforts of the entire health system are currently aimed to face the current viral emergency, cancer diseases continue to cause the death of thousands of people. It is clear that our efforts must be directed to protect the population from the virus by treating positive cases, while also guaranteeing life-saving treatments to patients suffering from chronic and tumor pathologies. The latter will be essential in order to limit, as much as possible, the increase in waiting times and to avoid exposing fragile patients to unnecessary infectious risks. The surgery selection criteria which prioritize the treatment of malignant breast lesions at immediate risk of life are leading to an accumulation of lesions included in B3 and C1 priority classes with a prolongation of their waiting times. With particular regard to this group of patients, as the positive predictive value for malignancy of lesions of uncertain malignant potential varies from 6 to 32%, according to different histotypes, this delay may compromise the prognosis of these patients. 14 Moreover, in case of a second outbreak of pandemic this new patient's pathway can help the hospital to guarantee the higher level of care and the safest method to treat breast oncologic patients with a minimum risk of contagion. At the end of the pandemic emergency, many benign and reconstructive cases will return to our attention. While their surgical treatment will be necessary as soon as possible, this will inevitably impose further stress on the hospital staff who is affected by the burden of the COVID-19 pandemic. https://orcid.org/0000-0002-2804-2814 Coronavirus disease 2019 The requirements of a specialist breast centre Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium Ottavio Nicastro (Coordinamento Rischio Clinic BA (OMS).[INDICATIONS FOR A RATIONAL USE OF PROTECTIONS FOR SARS-COV-2 INFECTION IN HEALTH, SOCIAL AND SANITARY ACTIVITIES (ASSISTANCE TO SUBJECTS AFFECTED BY COVID-19 Incisional negative pressure wound therapy for prevention of wound healing complications following reduction mammaplasty The efficacy of prophylactic negative pressure wound therapy for closed incisions in breast surgery: A systematic review and meta-analysis Temporary, customized negative pressure wound therapy to assist wound closure in selected patients: A practical solution or a bridge to advanced care Subcutaneous expanders and synthetic mesh for breast reconstruction: Long-term and patient-reported BREAST-Q outcomes of a single-center prospective study Subcutaneous direct-to-implant breast reconstruction: Surgical, functional, and aesthetic results after long-term follow-up TiLoop ® Bra mesh used for immediate breast reconstruction: comparison of retropectoral and subcutaneous implant placement in a prospective single-institution series Subcutaneous tissue expander placement with synthetic titanium-coated mesh in breast reconstruction: Long-term results High risk (B3) breast lesions: What is the incidence of malignancy for individual lesion subtypes? A systematic review and meta-analysis The patient's pathway for breast cancer in the COVID-19 era: An Italian single-center experience